Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

BACKGROUND: Metaplastic breast cancer (MpBC) is an aggressive subtype of breast carcinoma that is often resistant to conventional chemotherapy. Therefore, novel treatment strategies are urgently needed. Immune check point inhibitors have shown activity in programmed death-ligand 1 (PD-L1) – positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Voutilainen, S., Heikkilä, P., Bartkova, J., Nevanlinna, H., Blomqvist, C., Bartek, J., Mattson, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743555/
https://www.ncbi.nlm.nih.gov/pubmed/36503417
http://dx.doi.org/10.1186/s12885-022-10408-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743555/
https://www.ncbi.nlm.nih.gov/pubmed/36503417
http://dx.doi.org/10.1186/s12885-022-10408-7

Ejemplares similares